Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2023-04-18 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司2022年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022年度内部控制评价报告' which translates to '2022 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2022, including financial and non-financial internal control defects, their identification, and rectification status. The document is a detailed report on internal control evaluation, not an announcement or certification. It contains substantive content about internal control standards, evaluation scope, and conclusions. This fits the description of an Audit Report / Information (AR), which includes audit reports and applied accounting principles related to internal controls, excluding full annual reports. The document length is 3837 characters, which is relatively short but contains detailed internal control evaluation content, not just a notice or announcement. Therefore, the best classification is AR with high confidence. FY 2022
2023-04-18 Chinese
圣湘生物科技股份有限公司关于2022年度日常关联交易确认及预计2023年度日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the confirmation of 2022 daily related party transactions and the forecast of 2023 daily related party transactions by 圣湘生物科技股份有限公司. It includes transaction amounts, related parties, approval procedures, independent directors' opinions, and compliance with stock exchange rules. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a regulatory announcement about related party transactions, which is a typical regulatory filing. There is no indication that this is a proxy statement, earnings release, or management report. The document is more detailed than a simple notice but does not contain full financial statements or audit opinions. Therefore, it fits best under Regulatory Filings (RNS).
2023-04-18 Chinese
圣湘生物科技股份有限公司2023年限制性股票激励计划（草案）摘要公告
Remuneration Information Classification · 95% confidence The document is a detailed announcement regarding a 2023 restricted stock incentive plan (股权激励计划) for 圣湘生物科技股份有限公司. It includes specifics about the stock incentive plan's purpose, scope, number of shares, pricing, vesting conditions, performance targets, accounting treatment, rights and obligations of the company and incentive recipients, adjustment methods, and procedures for implementation, changes, and termination. The content is focused on management compensation and stock incentive arrangements for directors and senior management, which aligns with remuneration and incentive disclosures. There is no indication that this is a full annual report, audit report, earnings release, or other financial report. It is not a proxy solicitation or voting results announcement, nor a general regulatory filing. The document is comprehensive and substantive, not a brief announcement or certification. Therefore, the best fitting category is Remuneration Information (DEF 14A), which covers detailed reports on compensation and incentive plans for executives and directors.
2023-04-18 Chinese
圣湘生物科技股份有限公司关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase program. It details the number of shares repurchased, the price range, total funds used, and compliance with regulatory guidelines. It does not contain financial statements or comprehensive financial data but rather updates on the share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2023-04-04 Chinese
圣湘生物科技股份有限公司独立董事关于第二届董事会2023年第三次临时会议相关事宜的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of the company regarding a specific board meeting held on March 14, 2023. It discusses the review and approval of a proposal related to foreign exchange hedging business. The document is short (471 characters) and focuses on board-related matters and independent directors' opinions rather than financial results or detailed reports. It does not contain financial statements or detailed financial data. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters, including independent directors' opinions on board meeting proposals.
2023-03-14 Chinese
圣湘生物科技股份有限公司关于开展外汇套期保值业务的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement by 圣湘生物科技股份有限公司 regarding the commencement of foreign exchange hedging business. It includes the purpose, transaction methods, amounts, risk analysis, risk control measures, accounting treatment, and opinions from independent directors, the supervisory board, and the sponsoring institution. The document is not a financial report or earnings release but a formal announcement of a capital/financing-related activity involving foreign exchange hedging to manage financial risk. It does not contain financial statements or quarterly/yearly results, nor is it a regulatory filing or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it relates to the company's financing and risk management activities involving foreign exchange hedging business.
2023-03-14 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.